Analyst Report: Upgrade for access 20/20 GeneSystems Makes Cancer Screening Affordable

20/20 GeneSystems offers an affordable test that screens for multiple types of cancers. But the market may not be ready for 20/20's solution.

Company: 20/20 GeneSystems
Security Type: Convertible Note
Valuation: $58,400,000
Min Investment: $500
Platform: StartEngine
Deadline: Dec 21, 2022
Teddy Lyons - November 9th, 2022

Blood Will Tell

Cancer is the most studied disease in the world. Just about everyone has been affected by it in one way or another. And when it comes to cancer treatment, the news is always the same — new experimental drugs, new trial therapies. Like you, I hope that we will have a cure for cancer one day. But right now, that day seems to be pretty far off.

In the meantime, what is the most effective way to address cancer? The answer is clear: early detection. When cancer is detected at Stage 1, survival rates increase substantially. (Most studies show at least five years of survival after early diagnosis.) However, the infrastructure in place for cancer detection is based on X-ray, magnetic resonance imaging, and other types of specialized technology. There is really no well-known alternative to these expensive, image-based tests. 

Well, the company I am introducing today — 20/20 GeneSystems — offers a blood-based cancer detection test for just $189. 20/20’s OneTest is the cheapest cancer test on the market and utilizes a method called tumor antigen detection. Tumor antigen testing has been around for decades. It detects the presence of cancer-specific proteins in the body. 20/20 increases the accuracy of traditional antigen tests by using artificial intelligence (AI) and algorithms, and it can find multiple types of cancer: colon, lung, ovarian, prostate, liver, stomach, and pancreatic.

How? Well, since 2018, the company has gotten access to the records of more than 200,000 patients with known cancer outcomes. Once a OneTest sample is received, 20/20 uses machine learning algorithms based on these medical records to predict the likelihood of a patient having cancer. Currently, the company is targeting individual consumers and high-risk occupational groups (like firefighters).

Now that you know what 20/20 GeneSystems is all about, let’s dig deeper into the performance of the business. 

Pay Annually - save 17%

This content requires: Edge

Data-driven startup investment ratings, AI analyst reports, and portfolio company exit and failure tracking

30 /month
25 /annually

What's included

  • Everything in Free plus
  • Data-driven investment ratings and AI analyst reports
  • Advanced company search table (with ratings and reports)
  • Markets page filters and historical industry data
  • Startup investment exit and failure tracker

Recent Analyst Reports

Analyst Report
Teeccino Is Ready for Explosive Growth

Teeccino Is Ready for Explosive Growth

Teeccino, a coffee alternative, has achieved product-market fit and is looking for explosive growth in the coming years.

Teddy Lyons Teddy Lyons

Teddy Lyons

Analyst Report
Zencastr Tackles Advertising and Monetization Problems for Podcasts

Zencastr Tackles Advertising and Monetization Problems for Podcasts

Zencastr, despite having just a few months of runway, has an impressive product that solves some major pain points for podcasters.

Olivia Strobl Olivia Strobl

Olivia Strobl

Analyst Report
Skillest Brings Golf Amateurs and Pros Together in the Best Way

Skillest Brings Golf Amateurs and Pros Together in the Best Way

Remote golf coaching app Skillest is attracting a growing population of golfers with enthusiastic coaches and free advertising.

Teddy Lyons Teddy Lyons

Teddy Lyons

Give your startup investing an edge by creating a free KingsCrowd account and getting started today.

Get a free weekly Pitch Review!

Sign up for our 3 minute newsletter with fresh takes on the top-rated investments and key startup trends you should know.

We care about the protection of your data. Read our Privacy Policy.